RxDoctor Payments Data

Bertha Ayi

Infectious Disease · Sioux Falls, SDNPI 1083670343

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.7% of the total across 8 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by AbbVie at 22.0% of the total. Reporting peaked in 2019 at $606 and has fallen 93.4% since, to $40 in 2025. Among infectious disease clinicians in SD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$692in general payments, 2019–2025

Across 8 payments — averaging $86.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$153
  • Johnson & Johnson$125
  • E.r. Squibb & Sons, L.L.C.$125
  • Viiv Healthcare Company$125
  • Paratek Pharmaceuticals, Inc.$109
  • Merck$40
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$67698%
  • Education$162%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$692 in reported general payments places this provider in the 90th percentile of 22 infectious disease providers in South Dakota.

See all infectious disease providers in South Dakota

Medicare billing

Part B allowed, 2024
$77,420
Medicare patients
199
Services billed
720

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala16$62,028
Daptomycin17$7,275
Vancomycin Hcl14$3,665
Atovaquone-Proguanil HclAtovaquone/Proguanil Hcl12$2,133
Fluconazole13$1,142
Cefazolin Sodium33$703
Cephalexin18$663
CeftriaxoneCeftriaxone Sodium21$383
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim13$229
Azithromycin24$188
Ciprofloxacin Hcl22$181

Paid to pharmacies, not to this prescriber.

Other infectious disease in Sioux Falls

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →